Basal cell carcinoma does metastasize.

Department of Surgery, University of California San Francisco, VA Medical Center San Francisco, California, USA.
Dermatology online journal 02/2008; 14(8):5.
Source: PubMed

ABSTRACT Basal cell carcinoma (BCC) rarely metastasizes. However, this unfortunate outcome can occur, usually in neglected tumors. We report a 52-year-old man with a BCC on the left chest that enlarged and then ulcerated over a 6-year period. Metastasis of the tumor to lymph nodes in the left axilla resulted, but the patient remains free of disease 24 months after wide excision, lymph node dissection, and local radiation therapy to the axilla.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Metastasis from basal cell carcinoma of the skin is very rare with cases being documented in the lymph nodes, lung, bone and parotid gland. The main histopathological differential diagnosis is the locally arising basal cell adenocarcinoma from which it is difficult to distinguish by morphology and routine immunohistochemistry. Approximately 85 % of all reported metastatic basal cell carcinomas arise in the head and neck region. Here we present a case of basal cell carcinoma of the skin of the left lateral canthus of the eye which metastasized to the intraparotid lymph nodes with infiltration of the adjacent parotid parenchyma. More awareness and vigilance is required on the part of the reporting pathologist to consider metastasis in the presence of a parotid tumour. Features favouring metastasis include history of primary cutaneous basal cell carcinoma, histological similarity to the primary lesion and absence of any demonstrable direct extension from the skin lesion. We also review the literature on metastatic basal cell carcinoma and discuss the need for adequate follow up in high risk patients.
    Head and Neck Pathology 11/2013;
  • Dermatologic Surgery 01/2013; 39(1 Pt 1):145. · 1.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current guidelines for certain cancer therapies mainly provide recommendations for therapy options treating the primary tumors. However, first-choice treatments for advanced or metastasizing tumors are described only rarely if at all. In such cases, one or more individual treatment options are chosen by the physician depending on the medical need of the patient and considering the acceptance of this treatment by the patient. Often, well-known drugs are selected with a different dosing than is indicated in the drug information leaflet. In other cases, drugs not yet approved for this particular type of cancer are used off label or certain therapies are used in combination or consecutively in a manner not reported before. With the increasing research on personalized medicine, particularly in treating cancer, case reports on innovative drug therapies or newly developed surgical interventions may provide extremely valuable information in instances where randomized controlled trials may not be feasible (eg, because of a low patient number or ethical considerations).
    Global advances in health and medicine : improving healthcare outcomes worldwide. 05/2012; 1(2):8-10.